ClinicalTrials.gg
CompletedNCT07066722Updated Mar 9, 2026

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

A Phase 1 interventional study of VH4524184 and Itraconazole in HIV Infections, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
84th of 210
126 · median 82
Started
2025
with 3 others
Phase 1
83 of 266
9 open now
Registered
256th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 84th largest by enrollment of the 210 interventional ones that give a count, is one of 4 that started in 2025, is one of 83 in phase 1, and was the 256th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The aim of the study is to gather information on how the drug behaves in healthy adults, how it is absorbed, and how it interacts when taken with other medicines.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Drug-drug interaction
  • First-time in human
  • HIV
  • Bioavailability
  • Healthy Adult Participants
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Participants must be 18 to 60 years of age inclusive at the time of signing the form (ICF).

2. Male or female

  1. Male Participants: No restrictions for male participants
  2. A female participant (female sex assigned at birth) is eligible to participate if she is not pregnant, or breastfeeding and the following condition applies: She is a woman of nonchildbearing potential (WONCBP).

    3. Participants who are overtly healthy as determined by medical evaluation 4. , ALT, alkaline phosphatase and ≤ 1.5 x (ULN) 6. Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of clinical conditions affecting drug absorption, metabolism, or elimination.,
  2. Pre-existing , gastro-intestinal pathology
  3. Abnormal glucose metabolism requiring insulin or medications.
  4. Clinically significant Abnormal blood pressure.
  5. History of Lymphoma, leukemia, or any within the past 5 years (3 years for resected basal or squamous epithelial carcinomas of skin).
  6. Breast cancer within the past 10 years.
  7. Current or chronic history of liver disease or known hepatic or biliary abnormalities.
  8. History of syncope, clinically significant palpitations, cardiac arrhythmias or cardiac disease or a family long syndrome.
  9. History of seizure(s) and / or other clinically significant neurological conditions.
  10. Pre-existing psychiatric condition, including depression, anxiety, and/or insomnia/sleep disturbances and / or suicidal ideation.
  11. History of drug .

13. Use of medications/supplements affecting cytochrome P450 enzymes within 7 to 14 days prior to dosing.

14. based on selected drug prescribing information. 15. Exposure to more than 4 new products within 12 months 16. Current enrollment or past participation in another investigational study in which an investigational intervention was administered within the last 30 days.

17. Estimated glomelular filtration rate () \< 90 mL/min or serum creatinine >1.1× [Inker, 2021].

18. \<12.5 g/dL for men and \<11 g/dL for women. 19. Presence of surface antigen (HBsAg) [and Hepatitis B core antibody (HBcAb)] at screening 20. Positive antibody test result at screening 21. Positive SARS-CoV-2 test, having signs and symptoms which in the opinion of the investigator are suggestive of COVID-19.

22.Positive pre- study drug/alcohol screen. 23. Poor metabolizers of CYP2C9 and / or CYP2C19 as assessed by genotype testing. HLA-B*1502 positive as applicable to specified cohort.

Other exclusion criteria 24. Regular alcohol consumption exceeding specified limits. 25. Regular use of known drugs of abuse. 26. Nicotine use within 6 months. 27. Sensitivity or allergy to the study drug. 28. >1.5×ULN. 29. Total >1.5×ULN. 30. Significant arrhythmias or findings that may compromise participant safety according to the investigator or VH Medical Monitor's assessment.

31. For eligibility determination, triplicate ECGs are required. The criteria are:

  • Heart Rate: Excludes males with \<45 or >100 bpm, females with \<50 or >100 bpm.
  • PR Interval: Excludes any PR intervals \<120 or >220 msec.
  • QRS Duration: Excludes durations \<70 or >120 msec.
  • QTcF Interval: Excludes intervals >450 msec.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Part 1A_VH4524184 (Sequence 1)

    Participants will receive VH4524184 tablet(s) of Dose level 1 followed by Dose level 2 in fasted condition.

    Drug: VH4524184

  • Experimental
    Part 1A_VH4524184 (Sequence 2)

    Participants will receive VH4524184 tablet(s) of Dose level 2 followed by Dose level 1 in fasted condition.

    Drug: VH4524184

  • Experimental
    Part 1A_VH4524184 (Sequence 3)

    Participants will receive VH4524184 tablet(s) of Dose level 3 followed by Dose level 2 in fasted condition.

    Drug: VH4524184

  • Experimental
    Part 1A_VH4524184 (Sequence 4)

    Participants will receive VH4524184 tablet(s) of Dose level 2 followed by Dose level 3 in fasted condition.

    Drug: VH4524184

  • Experimental
    Part 1B_VH4524184 (Sequence 5)

    Participants will receive VH4524184 tablet of Dose level 2 in fasted condition and then followed by intake of a high fat meal.

    Drug: VH4524184

  • Experimental
    Part 1B_VH4524184 Sequence 6)

    Participants will receive VH4524184 tablet of Dose level 2 following a high fat meal and then in fasted condition.

    Drug: VH4524184

  • Experimental
    Part 1B_VH4524184 (Sequence 7)

    Participants will receive VH4524184 tablet of Dose level 3 in fasted condition and then followed by intake of a high fat meal.

    Drug: VH4524184

  • Experimental
    Part 1B_VH4524184 (Sequence 8)

    Participants will receive VH4524184 tablet of Dose level 3 following a high fat meal and then in a fasted condition.

    Drug: VH4524184

  • Experimental
    Part 2_Cohort 1

    Participants will receive VH4524184 tablet and Itraconazole.

    Drug: VH4524184 · Drug: Itraconazole

  • Experimental
    Part 2_Cohort 2A

    Participants will receive VH4524184 and Rifabutin.

    Drug: VH4524184 · Drug: Rifabutin

  • Experimental
    Part 2_Cohort 2B

    Participants will receive VH4524184 tablet and Phenytoin.

    Drug: VH4524184 · Drug: Phenytoin

  • Experimental
    Part 2_ Cohort 3

    Participants will receive Metformin, Digoxin and VH4524184 tablets.

    Drug: VH4524184 · Drug: Metformin · Drug: Digoxin

Interventions

  • VH4524184 will be administered.

  • DrugItraconazole

    Itraconazole will be administered.

    Also known as: Sporanox

  • Rifabutin will be administered.

    Also known as: Mycobutin

  • DrugPhenytoin

    Extended phenytoin sodium will be administered.

    Also known as: Dilantin

  • DrugMetformin

    Metformin will be administered.

    Also known as: Glumetza

  • DrugDigoxin

    Digoxin will be administered.

    Also known as: Lanoxin

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum plasma concentration (Cmax) for VH4524184

    Time frame: Up to Day 18

  2. Part 1: Area under the concentration-time curve from 0 to tau (AUC0-t) for VH4524184

    Time frame: Up to day 18

  3. Part 1: Area under the concentration-time curve from 0 to infinity (AUC0-inf) for VH4524184

    Time frame: Up to day 18

  4. Part 2: Cmax for VH4524184

    Time frame: At Day 1, Day 14, Day 19 and Day 22

  5. Part 2: AUC0-t of VH4524184

    Time frame: At Day 1, Day 14, Day 19 and Day 22

  6. Part 2: AUC0-inf of VH4524184

    Time frame: At Day 1, Day 14, Day 19 and Day 22

  7. Part 2: Cmax for metformin

    Time frame: At Day 1 and Day 15

  8. Part 2: AUC0-t for metformin

    Time frame: At Day 1 and Day 15

  9. Part 2: Cmax for Digoxin

    Time frame: At Day 1 and Day 15

  10. Part 2: AUC0-t for Digoxin

    Time frame: At Day 1 and Day 15

Secondary outcomes

  1. Number of participants with adverse events (AEs) and severity of AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of grades are defined as Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially Life- Threatening.

    Time frame: From Day 1 up to Day 42

  2. Number of participants with AEs leading to discontinuation of study intervention

    Time frame: Throughout the study treatment period (from Day 1 up to Day 33)

  3. Number of participants with Change in laboratory parameters

    Time frame: From Day 1 up to Day 42

  4. Number of participants with maximum toxicity grade increase from baseline in laboratory parameters

    Toxicity is graded using the DAIDS criteria Version 2.1 where grades were defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening. A higher grade indicates greater severity.

    Time frame: From Day 1 up to Day 42

  5. Part 1: Time to maximum concentration (Tmax) of VH4524184

    Time frame: At Day 1

  6. Part 1: Apparent Terminal Half Life (T1/2) of VH4524184

    Time frame: At Day 1

  7. Part 1: Apparent oral clearance (CL/F) of VH4524184

    Time frame: At Day 1

  8. Part 2: Tmax of VH4524184 Following Single-Dose Administration with CYP3A4 Inhibitors and Inducers (Itraconazole, Rifabutin, Phenytoin)

    Time frame: At Day 1, Day 14, Day 19 and Day 22

  9. Part 2: T1/2 of VH4524184 Following Single-Dose Administration with CYP3A4 Inhibitors and Inducers (Itraconazole, Rifabutin, Phenytoin)

    Time frame: At Day 1, Day 14, Day 19 and Day 22

  10. Part 2: CL/F of VH4524184 Following Single-Dose Administration with CYP3A4 Inhibitors and Inducers (Itraconazole, Rifabutin, Phenytoin)

    Time frame: At Day 1, Day 14, Day 19 and Day 22

  11. Part 2: Cmax for VH5424184 Following Comedication with Transporter Substrates with metformin and digoxin

    Time frame: At Day 1 and Day 15

  12. Part 2: AUC0-t for VH5424184 Following Comedication with Transporter Substrates metformin and digoxin

    Time frame: At Day 1 and Day 15

  13. Part 2: Cmax for Itraconazole Following Comedication with VH4524184

    Time frame: At Day 1 and Day 14

  14. Part 2: AUC0-t for Itraconazole Following Comedication with VH4524184

    Time frame: At Day 1 and Day 14

  15. Part 2: Cmax for Rifabutin Following Comedication with VH4524184

    Time frame: At Day 1 and Day 11

  16. Part 2: AUC0-t for Rifabutin Following Comedication with VH4524184

    Time frame: At Day 1 and Day 19

  17. Part 2: Cmax for Phenytoin Following Comedication with VH4524184

    Time frame: Day 1 and Day 22

  18. Part 2: AUC0-t for Phenytoin Following Comedication with VH4524184

    Time frame: Day 1 and Day 22

07

Study locations

2 sites
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 5 months is close to that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 15, 2025
StartActual
Jul 7, 2025
Primary completionActual
Dec 17, 2025
CompletionActual
Dec 17, 2025
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07066722
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Jul 7, 2025
Primary completion
Dec 17, 2025
Completion
Dec 17, 2025
Last update
Mar 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VH4524184

Start the discussion